Evidence map›Paper›PMID 37565226›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2023

Effects of Ninjin'yoeito on Human

Marisa Kaneda, Manami Oyama, Takashi Yoshimi, Seiwa Michihara, Li-Kun Han, Nina Fujita, Ryuji Takahashi

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Marisa KanedaKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.ORCID https://orcid.org/0009-0004-8064-4881
Manami OyamaKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.
Takashi YoshimiKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.
Seiwa MichiharaKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.ORCID https://orcid.org/0000-0002-6774-478X
Li-Kun HanKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.
Nina FujitaKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.
Ryuji TakahashiKampo Research Laboratories, Kracie Pharma, Ltd., 3-1 Kanebo-machi, Takaoka-shi, Toyama 933-0856, Japan.ORCID https://orcid.org/0000-0002-7432-4257
Kaneka (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ninjin'yoeito (NYT) is widely used clinically for the management of patients with frailty and other multiple symptoms. NYT is often administered with other drugs; however, little information is available on its drug interactions. Previous studies using human liver microsomes have reported that constituents of NYT either inhibit (schisandra fruit, cinnamon bark, glycyrrhiza, and poria sclerotium) or induce (schisandra fruit and glycyrrhiza) CYP3A4 expression. Herein, we conducted in vitro and in vivo studies targeting human CYP3A and mouse CYP3A to elucidate the effects of NYT coadministration with other drugs on hepatic drug metabolism. In an inhibition study using human liver microsomes, NYT showed concentration-dependent reversible inhibition and time-dependent inhibition. Furthermore, in an induction study using frozen human hepatocytes, the addition of 0.01-0.1 mg/mL NYT resulted in a concentration-dependent increase in CYP3A gene expression. Contrarily, no significant changes in CYP3A substrate blood concentrations were observed between untreated mice and mice that received either a single dose of NYT or repeated doses for 15 days. These results demonstrate that NYT has inhibitory and inductive effects on hepatic CYP3A in vitro, but orally administered NYT does not affect drug metabolism mediated by hepatic CYP3A in vivo in the mouse model. Although there is a little information about drug interactions of NYT, this study provides new evidence for that.

Identifiers

PMID37565226
PMCPMC10412298
OpenAlexW4385479561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.